2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015
DateTitle 
05/17/18Nuvectra to Present at Two Upcoming Investor Conferences
PLANO, Texas, May 17, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at two upcoming investor conferences in June 2018.                   Event:   Jefferies 2018 Global Healthcare Conference   ... 
Printer Friendly Version
05/02/18Nuvectra™ Reports First Quarter 2018 Financial Results
PLANO, Texas, May 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2018. Highlights Reported consolidated revenues of $10.6 million for the first quarter 2018, including total Algovita® sales of $9.1 million. Expanded U.S. commercial team. Completed follow-on public offering of common stock for gross proceeds of approximately $26.0 million in February... 
Printer Friendly Version
04/23/18Nuvectra™ to Report First Quarter 2018 Financial Results on May 2, 2018
PLANO, Texas, April 23, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2018 on Wednesday, May 2, 2018 after market close. Nuvectra will hold a conference call on Wednesday, May 2, 2018, at 4:30pm ET to discuss the results. The dial-in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conferen... 
Printer Friendly Version
03/06/18Nuvectra™ Reports Fourth Quarter and Full Year 2017 Financial Results
Record Quarterly Algovita® Revenue of $10.4 Million PLANO, Texas, March 06, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the fourth quarter and full year ended December 31, 2017. Recent Company Highlights Reported record consolidated revenues of $12.0 million for the fourth quarter 2017 and $31.8 million for the full year 2017. Achieved the 1,000th Algovita® SCS System implantation in U... 
Printer Friendly Version
02/27/18Nuvectra to Present at Two Upcoming Investor Conferences
PLANO, Texas, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at two upcoming investor conferences. Event: Cowen and Company 38th Annual Health Care Conference  Date: Monday, March 12, 2018  Time: 2:10 p.m. ET ... 
Printer Friendly Version
02/22/18Nuvectra™ to Report Fourth Quarter and Full Year 2017 Financial Results on March 6, 2018
PLANO, Texas, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2017 on Tuesday, March 6, 2018 after market close. Nuvectra will hold a conference call on Tuesday, March 6, 2018, at 4:30pm ET to discuss the results. The dial-in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international call... 
Printer Friendly Version
02/20/18Nuvectra Secures $45 Million Second Amendment to Existing Loan and Security Agreement
Agreement Provides Company with Increased Financial Flexibility and Extended Amortization Period PLANO, Texas, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has reached an agreement with Silicon Valley Bank and Oxford Finance, the lenders of its existing credit facility, to secure a second amendment to the Company’s loan and security agreement for $45.0 million. On February 16, 2018, the Company amende... 
Printer Friendly Version
02/05/18Nuvectra™ Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PLANO, Texas, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today the closing of its underwritten follow-on public offering of 3,248,750 shares of its common stock at a price to the public of $8.00 per share, which included the exercise in full by the underwriters of their option to purchase 423,750 additional shares of common stock on the same terms and conditions. Gross proceeds to Nuvectra were approximately $26.0 ... 
Printer Friendly Version
02/01/18Nuvectra™ Announces Pricing of Follow-On Stock Offering
PLANO, Texas, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today the pricing of its underwritten follow-on public offering of 2,825,000 shares of its common stock at a price to the public of $8.00 per share. The offering is expected to close on or about February 5, 2018, subject to customary closing conditions. In addition, Nuvectra has granted the underwriters a 30-day option to purchase up to 423,750 additional sha... 
Printer Friendly Version
01/31/18Nuvectra™ Announces Proposed Follow-On Stock Offering
PLANO, Texas, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it is commencing an underwritten follow-on public offering of its common stock. In addition, Nuvectra intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Nuvectra intends to use the net proceeds from this offering to fund the expansion of product development and commercialization activities, as well ... 
Printer Friendly Version
01/08/18Nuvectra™ Announces Preliminary Unaudited Fourth Quarter and Full Year 2017 Revenue
PLANO, Texas, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2017. Preliminary unaudited fourth quarter consolidated revenue is expected to be in the range of $11.5 to $12.0 million, compared to $4.2 million in the fourth quarter of 2016. Preliminary unaudited Algovita revenue for the fourth quarter of 2017 is expected to be ... 
Printer Friendly Version
01/03/18Nuvectra Announces Analyst & Investor Meeting at NANS 2018
Event to Feature Leading Physician Presentations on Nuvectra’s Algovita system PLANO, Texas, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the company will host an Analyst & Investor Meeting on Friday, January 12th during the 2018 North American Neuromodulation Society (NANS) Annual Meeting in Las Vegas, NV. The meeting will feature presentations by leading neuromodulation physicians Giancarlo Barolat,... 
Printer Friendly Version